Florida Cancer Specialists Contributes to FDA Approvals for Breast and Pancreatic Cancer Treatments
Florida Cancer Specialists & Research Institute (FCS) played a key role in the development of two newly approved cancer therapies by the U.S. Food and Drug Administration (FDA). These treatments, camizestrant for advanced breast cancer and daraxonrasib for metastatic pancreatic cancer, represent significant advancements in oncology care. Camizestrant was granted accelerated approval to treat HR-positive, HER2-negative breast cancers with ESR1 mutations that become resistant to hormone therapy. FCS contributed through Phase 1 and Phase 3 trials showing improved progression-free survival compared to standard treatments. Daraxonrasib received FDA approval for metastatic pancreatic cancer after clinical data demonstrated a median overall survival of 13.2 months, nearly double the control group's 6.7 months. FCS has been instrumental in advancing these therapies from early-stage research into approved treatments over recent years. The organization continues to lead community-based oncology research and is actively involved in exploring new applications for both approved and investigational drugs.
